TMCnet News
HLA Typing For Transplant Market By Technology, Products & Services, Application, End User Forecast To 2021NEW YORK, Sept. 29, 2016 /PRNewswire/ -- The global transplant diagnostics market is projected to reach USD 753.9 million by 2021 from USD 535.0 million in 2016, growing at a CAGR of 7.1%, during 2016 to 2021. Market growth can be attributed to factors such as rising number of solid organ, soft tissue, and stem cell transplantations; technological advancements; and increased funding, research grants, and public-private investments. However, high device costs associated with NGS and PCR-based devices and limited medical reimbursements for organ donation and transplantation procedures restrain the growth of the transplant diagnostics market. Furthermore, the technological shift from serological assays to gene-based HLA profiling and improving healthcare infrastructure across developing countries provide various opportunities in the transplant diagnostics market. The significant gap between the number of organs donated and the number of organs required annually is however a major challenge limiting the growth of the global transplant diagnostics market to a certain extent. In this report, the global transplant diagnostics market is segmented on the basis of technology into molecular assay technology [including PCR-based (sequence-specific oligonucleotide and sequence-specific primer-PCR) and sequencing-based (next-generation sequencing and Sanger sequencing)] and non-molecular assay technology (includes serological and mixed lymphocyte culture assay); products and services (reagents and consumables, instruments, and software & services); applications (diagnostic and research); and end users (hospitals & transplant centers, commercial service providers, and research laboratories & academic institutes). Geographically, North America and Europe are expected to be the mature markets for transplant diagnostics products in 2016. The North American transplant diagnostics market is expected to hold the largest share of global transplant diagnostics market in 2016; it is projected to grow at the highest CAGR during he forecast period owing to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS), increasing prevalence of target diseases (such as cancer, heart failure, and renal diseases) in the U.S. and Canada, and continuous technological advancements in the field of transplant diagnostics. As of 2015, the key players in the transplant diagnostics market included Thermo Fischer Scientific, Inc. (U.S.), Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others. Reasons to Buy the Report: The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms to garner a higher market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares. The report provides insights on the following pointers: Read the full report: http://www.reportlinker.com/p04141113-summary/view-report.html About Reportlinker __________________________
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hla-typing-for-transplant-market-by-technology-products--services-application-end-user-forecast-to-2021-300336997.html SOURCE Reportlinker 
|